ClinicalTrials.gg
CompletedNCT03349567Updated Apr 28, 2021Results posted

Improving Antimicrobial-Prescribing in Emergency Departments

An interventional study of Audit-and-feedback in Anti-Bacterial Agents and Respiratory Tract Infections, sponsored by Iowa City Veterans Affairs Medical Center. Completed at 2 sites in United States. Per ClinicalTrials.gov, last updated 2021-04-28.

Sponsored by Iowa City Veterans Affairs Medical Center · Not applicable, Interventional, and Health services research

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Non-randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 210 studies in Respiratory Tract Infections with a site in United States — 20 open to participants now, 28 under way, 5 of them phase 3. Respiratory Tract Infections · United States.

Enrollment
140th of 160
27 · median 137
Started
2018
with 9 others
No phase
66 of 210
9 open now
Registered
112th of 210
by date

Among the 210 studies in Respiratory Tract Infections with a site in United States, this one is the 140th largest by enrollment of the 160 interventional ones that give a count, is one of 10 that started in 2018, is one of 66 with no phase, and was the 112th registered.

Respiratory Tract Infections

753 studies on the registry are indexed under Respiratory Tract Infections; 112 are open to participants now.

Browse Respiratory Tract Infections studies →

Open to participants now

20 of the 210 studies in Respiratory Tract Infections with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 73 Respiratory Tract Infections studies recruiting now, 33 (45%) set no upper age limit and 32 (44%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 210 studies in Respiratory Tract Infections with a site in United States, or all of them as a file.
02

Study summary

Antimicrobial resistance is one of today's most urgent public health problems. One of the most important strategies to slow the spread of antimicrobial resistance is the promotion of judicious antimicrobial use. There are tremendous opportunities to reduce unnecessary antimicrobial-prescribing, particularly in Emergency Departments (EDs). In this study, the investigators will work collaboratively with ED providers in the Veterans Health Administration (VHA) to reduce unnecessary antimicrobial use. Academic-detailing and an audit-and-feedback intervention will be implemented, and the study will assess how overall antimicrobial-prescribing changes once these interventions are performed. ED providers will be shown how their antimicrobial-prescribing compares to their peers, thereby encouraging them to consider their professional reputation when making prescribing decisions. To assess the impact of this intervention, the study will monitor providers' antimicrobial-prescribing behavior through an automated metric, i.e. number of antimicrobial prescriptions per number of patient-visits. To assess changes in the appropriateness of antimicrobial-prescribing, the study team will also perform manual chart reviews and compare prescribing decisions to published guidelines.

Read the detailed description

Using a quasi-experimental design, the study team will work collaboratively with ED providers in the Veterans Health Administration (VHA) to improve antimicrobial-prescribing. Academic-detailing and an audit-and-feedback intervention will be implemented. Through audit-and-feedback, providers will be shown how their antimicrobial-prescribing compares to their peers, thereby encouraging them to consider their professional reputation when making prescribing decisions.

The study will use a pretest-posttest design (quasi-experimental design with a non-equivalent control group) to assess the effect of our pilot intervention at 2 participating EDs and 2 control EDs. For each ED, the pretest period will be the 12 months prior to the intervention. The intervention itself will last 12 months.

There will be an estimated 30 ED providers at the 2 study sites and 30 ED providers at the 2 control sites. Only antimicrobial prescriptions to patients discharged from the ED will be evaluated.

The primary outcome will be antimicrobial-prescribing volume adjusted for the total number of patient-visits. Secondary outcomes include the frequency of guideline-discordant antimicrobial-prescribing and adverse events.

At the conclusion of the pilot trial, a quasi-experimental interrupted time-series (ITS) analysis will be performed to assess the change in monthly antimicrobial usage for the 2 intervention sites combined and the 2 control sites combined. The time frame for this ITS analysis will be the one-year prior to the pilot trial's initiation through the trial's 1-year intervention period for a total of 24 months. In addition, a multivariable analysis will be performed to identify predictors of guideline-discordant therapy.

03

Conditions studied

  • Anti-Bacterial Agents
  • Respiratory Tract Infections
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

--An ED provider at one of the intervention or control sites.

Exclusion criteria

Exclusion Criteria:

--An ED provider who sees less than 100 patients in the ED per year.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Audit-and-feedback

    The experimental arm will consist of Emergency Department providers who do receive the intervention.

    Behavioral: Audit-and-feedback

  • No intervention
    Control

    The control arm will consist of providers who do not receive the intervention.

Interventions

  • BehavioralAudit-and-feedback

    We will monitor the antimicrobial-prescribing of providers in the experimental arm. Our study team will meet with providers in the experimental arm to provide guidance on optimal antimicrobial-prescribing. We will provide personalized feedback to providers in the experimental arm once every quarter.

    Also known as: Academic detailing

06

What researchers measure

Primary outcomes

  1. Percentage of Patient-visits Prescribed an Antimicrobial at Their ED Visit

    This outcomes is defined as the total number of antimicrobial-prescribing visits divided by the total number of patient-visits. This metric will be calculated on a monthly basis for each site (2 intervention, 2 control). It will be calculated during the baseline and intervention periods. Therefore, each site will contribute 24 data points.

    Time frame: This outcome will be calculated every month during the baseline and intervention periods. An interrupted time-series analysis will be performed to evaluate how this monthly percentage changed after the intervention period began.

Secondary outcomes

  1. Percentage of Patient-visits Prescribed a Late Antimicrobial Prescription More Than 24 Hours After But Within 30 Days of Their ED Visit

    Late antimicrobial prescription is defined as the prescription of an (additional) antimicrobial by any provider more than 24 hours after but within 30 days of the patient's ED visit.

    Time frame: For both intervention and control sites, the outcome will be reported as a monthly median, which is calculated across the 12 baseline and the 12 intervention months.

  2. Percentage of Patient-visits Who Were Hospitalized More Than 24 Hours After But Within 30 Days of Their ED Visit

    Hospitalization is defined as the need for hospitalization for any indication at a VA-facility more than 24 hours after but within 30 days of the patient's index visit to the ED.

    Time frame: For both intervention and control sites, the outcome will be reported as a monthly median, which is calculated across the 12 baseline and the 12 intervention months.

  3. Percentage of Patient-visits Who Died More Than 24 Hours After But Within 30 Days of Their ED Visit

    Death is defined as all-cause death more than 24 hours after and within 30-days of the patient's ED visit.

    Time frame: For both intervention and control sites, the outcome will be reported as a monthly median, which is calculated across the 12 baseline and the 12 intervention months.

  4. Percentage of Patient-visits Who Underwent Clostridium Difficile Testing More Than 24 Hours After But Within 30 Days of Their ED Visit

    Clostridium difficile testing is defined as a laboratory test for Clostridium difficile ordered more than 24 hours after but within 30-days of the patient's ED visit.

    Time frame: For both intervention and control sites, the outcome will be reported as a monthly median, which is calculated across the 12 baseline and the 12 intervention months.

  5. Percentage of Patient-visits Who Received Guideline Concordant Antimicrobial Management

    This outcome was assessed using blinded manual chart reviews in a randomly selected sample of patients that met inclusion criteria, as outlined in our study protocol. For this reason, the denominators for this outcome will not match the patient counts for the other outcomes. If a patient received an antimicrobial when indicated or did not receive an antimicrobial when not indicated, the patient was deemed to have received guideline-concordant management. During the baseline period, 497 charts were randomly selected for review, and 480 ultimately underwent adjudication. During the intervention period, 576 charts were randomly selected for review, and 455 underwent adjudication.

    Time frame: For the baseline and intervention periods, this outcome will be reported as the percentage of patients who received guideline-concordant management among the sample of qualifying ED visits that were randomly selected for manual chart review.

  6. Percentage of Patient-visits Prescribed an Antibiotic at Their ED Visit

    This outcomes is defined as the total number of antibacterial-prescribing visits divided by the total number of patient-visits. This metric will be calculated on a monthly basis for each site (2 intervention, 2 control). It will be calculated during the baseline and intervention periods. Therefore, each site will contribute 24 data points.

    Time frame: This outcome will be calculated every month during the baseline and intervention periods. An interrupted time-series analysis will be performed to evaluate how this monthly percentage changed after the intervention period began.

07

Results

Posted Apr 28, 2021
Limitations and caveats
Because the study was not randomized, we cannot exclude temporal confounding or selection bias. By conducting a time-series analysis, we tried to account for confounders that may change over time, and by including a matched-control group, we tried to minimize the possibility of regression to the mean. Second, we cannot exclude the possibility that sites had any other processes in place that could have influenced our outcomes.

Participant flow

We performed a quasi-experimental study with an interrupted time-series design and a matched-pair non-equivalent control group. There were 2 intervention sites and 2 control sites; 27/31 providers were enrolled at intervention sites. We measured outcomes in the PATIENTS seen at these 4 EDs. In a difference-in-differences analysis, outcomes were compared across intervention and control sites in patients seen before the intervention period (i.e. baseline) to those during the intervention period.

Participant flow — Overall Study
MilestoneAudit-and-feedbackControl
Started22
Completed22
Not completed00

Outcome measures

PrimaryPercentage of Patient-visits Prescribed an Antimicrobial at Their ED Visit

This outcomes is defined as the total number of antimicrobial-prescribing visits divided by the total number of patient-visits. This metric will be calculated on a monthly basis for each site (2 intervention, 2 control). It will be calculated during the baseline and intervention periods. Therefore, each site will contribute 24 data points.

Time frame:
This outcome will be calculated every month during the baseline and intervention periods. An interrupted time-series analysis will be performed to evaluate how this monthly percentage changed after the intervention period began.
Reported as:
Number · percentage of visits prescribed an abx
Percentage of Patient-visits Prescribed an Antimicrobial at Their ED Visit
percentage of visits prescribed an abxPatients Seen in the ED at Audit-and-feedback SitesPatients Seen in the ED at Control Sites
Baseline21.220.9
Intervention period19.121.6
Statistical analysis
  • Patients Seen in the ED at Audit-and-feedback Sites vs Patients Seen in the ED at Control Sites · Mixed Models Analysis · p = 0.35 · Incident rate ratio: 0.99 · 95% CI 0.98 to 1.01Segmented regression analysis was conducted using generalized linear models to estimate change in monthly antimicrobial prescription rates.
SecondaryPercentage of Patient-visits Prescribed a Late Antimicrobial Prescription More Than 24 Hours After But Within 30 Days of Their ED Visit

Late antimicrobial prescription is defined as the prescription of an (additional) antimicrobial by any provider more than 24 hours after but within 30 days of the patient's ED visit.

Time frame:
For both intervention and control sites, the outcome will be reported as a monthly median, which is calculated across the 12 baseline and the 12 intervention months.
Reported as:
Median · percentage of visits exposed to late abx
Percentage of Patient-visits Prescribed a Late Antimicrobial Prescription More Than 24 Hours After But Within 30 Days of Their ED Visit
percentage of visits exposed to late abxPatients Seen in the ED at Audit-and-feedback SitesPatients Seen in the ED at Control Sites
Baseline31.5 (28.6 to 36.1)29.5 (26.5 to 31.9)
Intervention31.1 (28.6 to 35.8)28.5 (25.4 to 32.5)
Statistical analysis
  • Patients Seen in the ED at Audit-and-feedback Sites vs Patients Seen in the ED at Control Sites · Incident rate ratio: 1.12 · 95% CI 0.93 to 1.35
SecondaryPercentage of Patient-visits Who Were Hospitalized More Than 24 Hours After But Within 30 Days of Their ED Visit

Hospitalization is defined as the need for hospitalization for any indication at a VA-facility more than 24 hours after but within 30 days of the patient's index visit to the ED.

Time frame:
For both intervention and control sites, the outcome will be reported as a monthly median, which is calculated across the 12 baseline and the 12 intervention months.
Reported as:
Median · percentage of visits hospitalized
Percentage of Patient-visits Who Were Hospitalized More Than 24 Hours After But Within 30 Days of Their ED Visit
percentage of visits hospitalizedPatients Seen in the ED at Audit-and-feedback SitesPatients Seen in the ED at Control Sites
Baseline5.9 (4.9 to 6.5)5.6 (4.9 to 6.1)
Intervention period5.9 (5.1 to 6.6)5.8 (5.2 to 6.3)
Statistical analysis
  • Patients Seen in the ED at Audit-and-feedback Sites vs Patients Seen in the ED at Control Sites · Incident rate ratio: 1.01 · 95% CI 0.81 to 1.27
SecondaryPercentage of Patient-visits Who Died More Than 24 Hours After But Within 30 Days of Their ED Visit

Death is defined as all-cause death more than 24 hours after and within 30-days of the patient's ED visit.

Time frame:
For both intervention and control sites, the outcome will be reported as a monthly median, which is calculated across the 12 baseline and the 12 intervention months.
Reported as:
Median · percentage of patient-visits who died
Percentage of Patient-visits Who Died More Than 24 Hours After But Within 30 Days of Their ED Visit
percentage of patient-visits who diedPatients Seen in the ED at Audit-and-feedback SitesPatients Seen in the ED at Control Sites
Baseline0.56 (0.4 to 0.7)0.61 (0.4 to 0.8)
Intervention period0.60 (0.4 to 0.7)0.59 (0.5 to 0.8)
Statistical analysis
  • Patients Seen in the ED at Audit-and-feedback Sites vs Patients Seen in the ED at Control Sites · Incident rate ratio: 0.88 · 95% CI 0.58 to 1.34
SecondaryPercentage of Patient-visits Who Underwent Clostridium Difficile Testing More Than 24 Hours After But Within 30 Days of Their ED Visit

Clostridium difficile testing is defined as a laboratory test for Clostridium difficile ordered more than 24 hours after but within 30-days of the patient's ED visit.

Time frame:
For both intervention and control sites, the outcome will be reported as a monthly median, which is calculated across the 12 baseline and the 12 intervention months.
Reported as:
Median · percentage of visits tested
Percentage of Patient-visits Who Underwent Clostridium Difficile Testing More Than 24 Hours After But Within 30 Days of Their ED Visit
percentage of visits testedPatients Seen in the ED at Audit-and-feedback SitesPatients Seen in the ED at Control Sites
Baseline0.60 (0.5 to 1.2)0.86 (0.7 to 1.2)
Intervention period0.69 (0.5 to 0.7)0.89 (0.7 to 1.2)
Statistical analysis
  • Patients Seen in the ED at Audit-and-feedback Sites vs Patients Seen in the ED at Control Sites · Incident rate ratio: 0.83 · 95% CI 0.53 to 1.29
SecondaryPercentage of Patient-visits Who Received Guideline Concordant Antimicrobial Management

This outcome was assessed using blinded manual chart reviews in a randomly selected sample of patients that met inclusion criteria, as outlined in our study protocol. For this reason, the denominators for this outcome will not match the patient counts for the other outcomes. If a patient received an antimicrobial when indicated or did not receive an antimicrobial when not indicated, the patient was deemed to have received guideline-concordant management. During the baseline period, 497 charts were randomly selected for review, and 480 ultimately underwent adjudication. During the intervention period, 576 charts were randomly selected for review, and 455 underwent adjudication.

Time frame:
For the baseline and intervention periods, this outcome will be reported as the percentage of patients who received guideline-concordant management among the sample of qualifying ED visits that were randomly selected for manual chart review.
Reported as:
Count of participants · Participants
Percentage of Patient-visits Who Received Guideline Concordant Antimicrobial Management
ParticipantsPatients Seen in the ED at Audit-and-feedback SitesPatients Seen in the ED at Control Sites
Baseline125123
Intervention166131
Statistical analysis
  • Patients Seen in the ED at Audit-and-feedback Sites · Chi-squared · p = 0.001
  • Patients Seen in the ED at Control Sites · Chi-squared · p = 0.13
SecondaryPercentage of Patient-visits Prescribed an Antibiotic at Their ED Visit

This outcomes is defined as the total number of antibacterial-prescribing visits divided by the total number of patient-visits. This metric will be calculated on a monthly basis for each site (2 intervention, 2 control). It will be calculated during the baseline and intervention periods. Therefore, each site will contribute 24 data points.

Time frame:
This outcome will be calculated every month during the baseline and intervention periods. An interrupted time-series analysis will be performed to evaluate how this monthly percentage changed after the intervention period began.
Reported as:
Median · % of visits prescribed an antibiotic
Percentage of Patient-visits Prescribed an Antibiotic at Their ED Visit
% of visits prescribed an antibioticPatients Seen in the ED at Audit-and-feedback SitesPatients Seen in the ED at Control Sites
Baseline20.8 (19.6 to 21.8)20.6 (18.7 to 22.2)
Intervention18.2 (16.8 to 19.6)20.6 (19.4 to 21.9)
Statistical analysis
  • Patients Seen in the ED at Audit-and-feedback Sites vs Patients Seen in the ED at Control Sites · Regression, Logistic · p = 0.46Segmented regression analysis was conducted using generalized linear models to estimate change in monthly antibiotic prescription rates.

Adverse events

Collected over Outcomes were tracked for 30 days after each ED patient visit.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Patients Seen at Audit-and-feedback ED Sites During Intervention Period141/23,164 (0.6%)1,593/23,164 (6.9%)11/23,164 (0%)
Patients Seen at Control ED Sites During the Intervention Period176/28,835 (0.6%)1,863/28,835 (6.5%)27/28,835 (0.1%)
Patients Seen at Audit-and-feedback ED Sites During the Baseline Period146/28,016 (0.5%)1,810/28,016 (6.5%)193/28,016 (0.7%)
Patients Seen at Control EDs During the Baseline Period197/33,077 (0.6%)2,031/33,077 (6.1%)321/33,077 (1%)
Most frequent serious events
Most frequent serious events
EventPatients Seen at Audit-and-feedback ED Sites During Intervention PeriodPatients Seen at Control ED Sites During the Intervention PeriodPatients Seen at Audit-and-feedback ED Sites During the Baseline PeriodPatients Seen at Control EDs During the Baseline Period
Hospitalization >24 hours after but within 30 days of ED visitGeneral disorders1452/231641687/288351664/280161834/33077
Mortality > 24 hours after ED visit and within 30 days of visitGeneral disorders141/23164176/28835146/28016197/33077
Most frequent other events
Most frequent other events
EventPatients Seen at Audit-and-feedback ED Sites During Intervention PeriodPatients Seen at Control ED Sites During the Intervention PeriodPatients Seen at Audit-and-feedback ED Sites During the Baseline PeriodPatients Seen at Control EDs During the Baseline Period
Clostridioides difficile infectionGastrointestinal disorders11/2316427/28835193/28016321/33077

Baseline characteristics

These numbers reflect patients seen in the 4 participating EDs during the baseline and intervention periods.

Age, Continuous
Age, Continuous(years)Patients Seen in the ED at Audit-and-feedback Sites During the Intervention PeriodPatients Seen in the ED at Control Sites During the Intervention PeriodPatients Seen in the ED at Audit-and-feedback Sites During the Baseline PeriodPatients Seen in the ED at Control Sites During the Baseline PeriodTotal
Median60 (59 to 62)60 (59 to 61)60 (58 to 62)60 (59 to 60)60 (59 to 61)
Sex: Female, Male
Sex: Female, Male(Participants)Patients Seen in the ED at Audit-and-feedback Sites During the Intervention PeriodPatients Seen in the ED at Control Sites During the Intervention PeriodPatients Seen in the ED at Audit-and-feedback Sites During the Baseline PeriodPatients Seen in the ED at Control Sites During the Baseline PeriodTotal
Female253226273014315911332
Male20,632262082500229918101760
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Patients Seen in the ED at Audit-and-feedback Sites During the Intervention PeriodPatients Seen in the ED at Control Sites During the Intervention PeriodPatients Seen in the ED at Audit-and-feedback Sites During the Baseline PeriodPatients Seen in the ED at Control Sites During the Baseline PeriodTotal
American Indian or Alaska Native2043362433611144
Asian3919070218517
Native Hawaiian or Other Pacific Islander5512594158432
Black or African American510627205990321517031
White1634323832198932732387391
More than one race3214033894671580
Unknown or Not Reported10961229133713354997
% of total visits prescribed an antimicrobial (monthly median)
% of total visits prescribed an antimicrobial (monthly median)(Percentage of visits prescribed an abx)Patients Seen in the ED at Audit-and-feedback Sites During the Intervention PeriodPatients Seen in the ED at Control Sites During the Intervention PeriodPatients Seen in the ED at Audit-and-feedback Sites During the Baseline PeriodPatients Seen in the ED at Control Sites During the Baseline PeriodTotal
Median19.1 (17.8 to 20.4)21.6 (19.9 to 22.4)21.2 (20.3 to 23.7)20.9 (19.4 to 23.4)20.7 (19.4 to 22.5)
08

Study locations

2 sites
  • Richard Roudebush VAMC
    Indianapolis, Indiana 46202, United States
  • Sioux Falls VA
    Sioux Falls, South Dakota 57105, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2018 to primary completion in Sep 2019, 11 months.

Results were first posted in Apr 2021, 1 year 6 months after primary completion.

Of 119 non-industry interventional studies with no phase under Respiratory Tract Infections, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's 11 months is below that.

Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 29.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2017
First posted
Nov 21, 2017
StartActual
Oct 9, 2018
Primary completionActual
Sep 30, 2019
CompletionActual
Oct 31, 2019
Results first posted
Apr 28, 2021
Last update
Apr 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03349567
Lead sponsor
Iowa City Veterans Affairs Medical Center
Responsible party
Daniel Livorsi (Physician-investigator, Iowa City Veterans Affairs Medical Center) — Principal investigator
First posted
Nov 21, 2017
Start date
Oct 9, 2018
Primary completion
Sep 30, 2019
Completion
Oct 31, 2019
Results posted
Apr 28, 2021
Last update
Apr 28, 2021

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion